Status:
UNKNOWN
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
Lead Sponsor:
Fudan University
Conditions:
Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.
Eligibility Criteria
Inclusion
- 18-75 years old.
- ECOG 0-1.
- Esophageal squamous cell carcinoma confirmed by pathology.
- No radiotherapy, chemotherapy, or other treatments prior to enrollment.
- Locally advanced esophageal squamous cell carcinoma (II-IVa, IVB with supraclavicular lymph node metastasis).
- No severe abnormal hematopoietic, cardiac, pulmonary, renal, hepatic function, or immunodeficiency.
- Informed consent signed.
Exclusion
- Less than 50.4Gy/28fx of radiotherapy dose.
- Without Concurrent chemotherapy.
- Pregnant or breastfeeding women or fertile patients who refused to use contraceptives.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05426850
Start Date
June 1 2021
End Date
December 1 2024
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai cancer center
Shanghai, Shanghai Municipality, China, 200032